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MATERIALS AND METHODS 
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In vitro cleavage reactions 
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Targeting a short cRNA substrate harbouring SCCMS 
mutations 
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Optimisation of reaction conditions 
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Cleavage of  cRNA transcripts containing the full 
coding region 
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